[Federal Register Volume 82, Number 172 (Thursday, September 7, 2017)]
[Notices]
[Page 42363]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18992]
[[Page 42363]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--The National Institute for Innovation in
Manufacturing Biopharmaceuticals
Notice is hereby given that, on July 18, 2017, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), the University of Delaware, doing
business as The National Institute for Innovation in Manufacturing
Biopharmaceuticals (``NIIMBL''), has filed written notifications
simultaneously with the Attorney General and the Federal Trade
Commission disclosing (1) the identities of the parties to the venture
and (2) the nature and objectives of the venture. The notifications
were filed for the purpose of invoking the Act's provisions limiting
the recovery of antitrust plaintiffs to actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act, the identities of the parties
to the venture are: University of Delaware, Newark, DE; Purdue
University, West Lafayette, IN; North Carolina State University,
Raleigh, NC; Rensselaer Polytechnic Institute, Troy, NY; Johns Hopkins
University, Baltimore, MD; Regents of University of Minnesota,
Minneapolis, MN; National Institute for Pharmaceutical Technology and
Education, Inc., Minneapolis, MN; University of Massachusetts, Lowell,
MA; Southwest Research Institute, San Antonio, TX; Tulane University,
New Orleans, LA; UNCW Research Foundation, or its assignee University
of North Carolina at Wilmington, Wilmington, NC; Carnegie Mellon
University, Pittsburgh, PA; East Carolina University, Greenville, NC;
University of Georgia Research Foundation, Athens, GA; Texas A&M
University System, College Station, TX; Clemson University, Clemson,
SC; The Pennsylvania State University, University Park, PA; Georgia
Tech Research Corporation, Atlanta, GA; Massachusetts Institute of
Technology, Cambridge, MA; University of Maryland College Park, College
Park, MD; Worcester Polytechnic Institute, Worcester, MA; Genentech,
San Francisco, CA; Stratophase LP, Romsey, UNITED KINGDOM; Chromatan
Corporation, State College, PA; ILC Dover LP, Frederica, DE; Sudhin
Biopharma Co., Superior, CO; Artemis Biosystems, Inc., Cambridge, MA;
Commissioning Agents, Indianapolis, IN; Unum Therapeutics, Inc.,
Cambridge, MA; RoosterBio, Inc., Avondale, PA; University of Maryland
Baltimore, Baltimore, MD; Forsyth Technical Community College, Winston-
Salem, NC; University of Pennsylvania, Philadelphia, PA; Celgene
Corporation, Summit, NJ; North Carolina Central University, Durham, NC;
Massachusetts Life Sciences Center, Waltham, MA; North Carolina
Biotechnology Center, Research Triangle Park, NC; Akron Biotechnology,
LLC, Boca Raton, FL; and Accugenomics, Inc., Wilmington, NC. The
general area of NIIMBL's planned activity is to engage in collaborative
activities with the goals of: (a) Accelerating biopharmaceutical
manufacturing innovation, (b) supporting the development of standards
that enable more efficient and rapid manufacturing capabilities, and
(c) educating and training a world-leading biopharmaceutical
manufacturing workforce. Additional information about NIIMBL can be
obtained from Dr. Kelvin Lee, Institute Director, NIIMBL, 15 Innovation
Way, Newark, DE 19711, [email protected] and (302) 831-3716.
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-18992 Filed 9-6-17; 8:45 am]
BILLING CODE P